In the context of rhabdomyosarcoma, and particularly in the fusion-positive (FP-RMS) subtype, DDX5 emerges as a central regulator of tumorigenesis, with implications for both disease progression and treatment. The gene discussed is DDX5; the disease is rhabdomyosarcoma.